{"analyses":[{"ciLowerLimit":"0.66","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.18","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3928","paramType":"Hazard Ratio (HR)","paramValue":"0.88","statisticalComment":"Strata: mutation status (KIT exon 9 vs. 11 vs. KIT/PDGFRA WT vs. other KIT {absence of exon 9 or 11}/PDGFRA) and intolerance to imatinib","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% confidence interval (CI) was not estimable due to fewer number of participants with events","groupId":"OG000","lowerLimit":"29.3","upperLimit":"NA","value":"35.5"},{"comment":"Upper limit of 95% confidence interval (CI) was not estimable due to fewer number of participants with events","groupId":"OG001","lowerLimit":"28.9","upperLimit":"NA","value":"30.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"227"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization until death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ripretinib (150 mg) once a day continuous dosing for 6-week (42 days) cycles","id":"OG000","title":"Ripretinib"},{"description":"Sunitinib (50 mg) once a day in 6-week (42 days) cycles with 4 weeks continuous dosing followed by 2 week break.","id":"OG001","title":"Sunitinib"}],"paramType":"MEDIAN","populationDescription":"All patient (AP) Intent to Treat (ITT) Population is defined as all patients who are randomized. Patients in this population will be analyzed according to the treatment they were scheduled to receive.","reportingStatus":"POSTED","timeFrame":"From date of randomization until death due to any cause (up to 3.33 years)","title":"Overall Survival (OS) in the All Patient (AP) Intent to Treat (ITT) Population","type":"SECONDARY","unitOfMeasure":"months"}